Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CD7 CAR-T for R/R CD7+ Hematologic Malignancies
NCT04480788Phase 1Unknown
- Sponsor
- PersonGen BioTherapeutics
- Start
- Nov 2020
- Primary completion
- Aug 2022
- Modality
- Gene Editing, Gene Silencing, CAR-T Cells
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of PA3-17 in T-cell acute lymphoblastic leukemia (T-ALL), T cell lymphoblastic lymphoma (T-LBL), Extranodal NK/T-cell lymphoma nasal type (ENKTCL-NT) and 4 more, sponsored by PersonGen BioTherapeutics. Primary endpoint: Dose-limiting toxicity up to 2 years. Status: unknown.
02
Drugs
PA3-17
03
Conditions
T-cell acute lymphoblastic leukemia (T-ALL)T cell lymphoblastic lymphoma (T-LBL)Extranodal NK/T-cell lymphoma nasal type (ENKTCL-NT)peripheral T-cell lymphoma (PTCL)angioimmunoblastic T-cell lymphoma (AITL)
Beyond the preview
Go deeper on NCT04480788.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04480788.